Table 4.
Cox proportional hazards regression analysis for risk of VL>400 copies/ml for the crude model and the adjusted model after multiple imputation of all covariates using lopinavir with a cutoff of 1 mg/l
| Crude model |
Adjusted model |
AICw |
||||
|---|---|---|---|---|---|---|
| Characteristic | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Lopinavir | ||||||
| >1 mg/l | Reference | – | Reference | – | Reference | – |
| <1 mg/l | 2.3 (1.63, 3.26) | 0.0001 | 2.11 (1.62, 2.75) | 0.001 | 2.14 (1.52, 3.02) | 0.0001 |
| Age | ||||||
| >10 months | Reference | – | Reference | – | – | – |
| <10 months | 1.07 (0.75, 1.52) | 0.70 | 1.04 (0.73, 3.95) | 0.81 | – | – |
| Pretreatment WAZ | ||||||
| Normal | Reference | – | Reference | – | – | – |
| Moderate | 1.06 (0.75, 1.48) | 0.72 | 0.91 (0.61, 1.33) | 0.63 | – | – |
| Severe | 1.87 (0.61, 1.25) | 0.45 | 1.15 (0.77, 1.72) | 0.49 | – | – |
| Pretreatment HAZ | ||||||
| Normal | Reference | – | Reference | – | Reference | – |
| Moderate | 2.24 (1.17, 4.28) | 0.015 | 2.20 (1.18, 4.09) | 0.012 | 2.32 (1.24, 4.37) | 0.009 |
| Severe | 2.92 (1.69, 5.03) | 0.0001 | 2.83 (1.66, 4.82) | 0.0001 | 2.90 (1.67, 5.05) | 0.0001 |
| Pretreatment logl0 VL | ||||||
| <5 | Reference | – | Reference | – | Reference | – |
| >5 | 1.67 (0.79, 3.50) | 0.17 | 1.69 (0.81, 3.53) | 0.16 | 1.58 (0.72, 3.44) | 0.252 |
| Pretreatment CD4% | ||||||
| ≥25% | Reference | – | Reference | – | – | – |
| <25% | 1.09 (0.69, 1.72) | 0.71 | 1.15 (0.74, 1.77) | 0.53 | – | – |
| WHO stage | ||||||
| 1 and 2 | Reference | – | Reference | – | – | – |
| 3 and 4 | 1.26 (0.75, 2.11) | 0.38 | 1.25 (0.73, 2.13) | 0.49 | – | – |
AICw, Akaike's information criterion with inverse probability weights; CD4%, CD4+ T-cell percentage; HAZ, height-for-age z-score; VL, viral load; WAZ, weight-for-age z-score.